Nervi F O, Del Pozo R, Covarrubias C F, Ronco B O
Hepatology. 1983 May-Jun;3(3):360-7. doi: 10.1002/hep.1840030314.
We tested the hypothesis that progesterone, an inhibitor of cholesterol esterification in liver microsomes, increases biliary cholesterol output by increasing the availability of cholesterol. Initial bile samples of 20 min were obtained from acute bile fistula rats after seven daily doses of progesterone (5 to 55 mg per kg of body weight). Biliary cholesterol output correlated with the doses of progesterone, r = 0.64 (p less than 0.005). A 100% increment in biliary cholesterol output was obtained with progesterone doses of 30 to 55 mg per kg of body weight. Under these conditions, biliary phospholipid output increased 50% (p less than 0.02), but bile salt output remained normal. The relationship between biliary cholesterol and phospholipids as a function of bile salt output was studied after acute depletion of the bile salt pool. A rectangular hyperbola was the best curve fitting for the experimental data in control and progesterone-injected rats. In the physiological range of bile salt output, between 60 and 120 nmoles per gm per min, progesterone-injected rats secreted 100% more biliary cholesterol than did controls. The calculated theoretical maximal cholesterol and phospholipid outputs were significantly increased in progesterone-injected animals. Serum and hepatic cholesterol pool, free and ester fractions, remained normal. The acyl-CoA: cholesterol acyltransferase reaction was 30% inhibited in hepatic microsomes of progesterone-injected rats, (p less than 0.05). The changes in biliary phospholipids and cholesterol output produced by progesterone were rapidly reversed by either 0.5% cholesterol feeding or 2 mg per kg of body weight ethynyl estradiol injection. These manipulations simultaneously produced a 100% increment in the microsomal acyl-CoA: cholesterol acyltransferase activity (p less than 0.005) and increased 4-fold the concentration of hepatic cholesterol esters. This experimental model suggests a functional interrelationship between biliary cholesterol output and the rate at which the liver esterifies cholesterol.
孕酮作为肝脏微粒体中胆固醇酯化作用的抑制剂,通过增加胆固醇的可利用性来提高胆汁中胆固醇的排出量。在给急性胆瘘大鼠每日注射七次孕酮(每千克体重5至55毫克)后,采集最初20分钟的胆汁样本。胆汁中胆固醇的排出量与孕酮剂量相关,r = 0.64(p小于0.005)。每千克体重30至55毫克的孕酮剂量可使胆汁中胆固醇排出量增加100%。在这些条件下,胆汁中磷脂排出量增加50%(p小于0.02),但胆盐排出量保持正常。在急性耗尽胆盐池后,研究了胆汁中胆固醇和磷脂与胆盐排出量之间的关系。对于对照大鼠和注射孕酮的大鼠,矩形双曲线最适合实验数据。在每克每分钟60至120纳摩尔的胆盐排出量生理范围内,注射孕酮的大鼠胆汁中胆固醇分泌量比对照大鼠多100%。计算得出的理论最大胆固醇和磷脂排出量在注射孕酮的动物中显著增加。血清和肝脏胆固醇池、游离和酯化部分均保持正常。注射孕酮的大鼠肝脏微粒体中酰基辅酶A:胆固醇酰基转移酶反应受到30%的抑制(p小于0.05)。通过喂食0.5%胆固醇或每千克体重注射2毫克乙炔雌二醇,可迅速逆转孕酮引起的胆汁中磷脂和胆固醇排出量的变化。这些操作同时使微粒体酰基辅酶A:胆固醇酰基转移酶活性增加100%(p小于0.005),并使肝脏胆固醇酯浓度增加四倍。该实验模型表明胆汁中胆固醇排出量与肝脏胆固醇酯化速率之间存在功能上的相互关系。